 |
|
Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
A Randomized Controlled Trial
Steven A. Kaplan, MD;
Claus G. Roehrborn, MD;
Eric S. Rovner, MD;
Martin Carlsson, MS;
Tamara Bavendam, MD;
Zhonghong Guan, MD, PhD
JAMA. 2006;296:2319-2328.
Context Men with overactive bladder and other lower urinary tract symptoms may not respond to monotherapy with antimuscarinic agents or  -receptor antagonists.
Objective To evaluate the efficacy and safety of tolterodine extended release (ER), tamsulosin, or both in men who met research criteria for both overactive bladder and benign prostatic hyperplasia.
Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted at 95 urology clinics in the United States involving men 40 years or older who had a total International Prostate Symptom Score of 12 or higher and, an International Prostate Symptom Score quality-of-life (QOL) item score of 3 or higher, a self-rated bladder condition of at least moderate bother, and a bladder diary documenting micturition frequency ( 8 micturitions per 24 hours) and urgency (3 episodes per 24 hours), with or without urgency urinary incontinence. Patients were recruited between November 2004 and February 2006, and the study was completed May 2006.
Interventions Patients were randomly assigned to receive placebo (n = 222), 4 mg of tolterodine ER (n = 217), 0.4 mg of tamsulosin (n = 215), or both tolterodine ER plus tamsulosin (n = 225) for 12 weeks.
Main Outcome Measures Patient perception of treatment benefit, bladder diary variables, International Prostate Symptom Scores, and safety and tolerability were assessed.
Results A total of 172 men (80%) receiving tolterodine ER plus tamsulosin reported treatment benefit by week 12 compared with 132 patients (62%) receiving placebo (P<.001), 146 (71%) receiving tamsulosin (P=.06 vs placebo), or 135 (65%) receiving tolterodine ER (P=.48 vs placebo). Patients receiving tolterodine ER plus tamsulosin compared with placebo experienced significant reductions in urgency urinary incontinence (–0.88 vs –0.31, P=.005), urgency episodes without incontinence (–3.33 vs –2.54, P=.03), micturitions per 24 hours (–2.54 vs –1.41, P<.001), and micturitions per night (–0.59 vs –0.39, P.02). Patients receiving tolterodine ER plus tamsulosin demonstrated significant improvements on the total International Prostate Symptom Score (–8.02 vs placebo, –6.19, P=.003) and QOL item (–1.61 vs –1.17, P=.003). All interventions were well tolerated. The incidence of acute urinary retention requiring catheterization was low (tolterodine ER plus tamsulosin, 0.4%; tolterodine ER, 0.5%; tamsulosin, 0%; and placebo, 0%).
Conclusions These results suggest that treatment with tolterodine ER plus tamsulosin for 12 weeks provides benefit for men with moderate to severe lower urinary tract symptoms including overactive bladder.
Clinical Trials Registration clinicaltrials.gov Identifier: NCT00147654
Author Affiliations: Department of Urology, Weill Cornell Medical College, New York, NY (Dr Kaplan); Department of Urology, University of Texas Southwestern Medical Center, Dallas (Dr Roehrborn); Department of Urology, Medical University of South Carolina, Charleston (Dr Rovner); Pfizer Inc, New York, NY (Mr Carlsson and Drs Bavendam and Guan).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
Toby C. Chai
JAMA. 2007;297(11):1191-1192.
EXTRACT
| FULL TEXT
Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
William Andrew Bell and Naseem Amarshi
JAMA. 2007;297(11):1192.
EXTRACT
| FULL TEXT
Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
James G. Young and Kesavapilla Subramonian
JAMA. 2007;297(11):1192-1193.
EXTRACT
| FULL TEXT
Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder—Reply
Steven A. Kaplan, Claus G. Roehrborn, Eric S. Rovner, Tamara Bavendam, and Zhonghong Guan
JAMA. 2007;297(11):1193.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Undisclosed Changes in Outcomes in Randomized Controlled Trials: An Observational Study
Ewart et al.
Ann Fam Med 2009;7:542-546.
ABSTRACT
| FULL TEXT
Overactive bladder in males
Gomelsky and Dmochowski
Therapeutic Advances in Urology 2009;1:209-221.
ABSTRACT
A Systematic Evaluation of Factors Associated With Nocturia--The Population-based FINNO Study
Tikkinen et al.
Am J Epidemiol 2009;170:361-368.
ABSTRACT
| FULL TEXT
Prospective pharmacologic therapies for the overactive bladder
Andersson
Therapeutic Advances in Urology 2009;1:71-83.
ABSTRACT
Efficacy and Safety of Extended-Release Oxybutynin in Combination With Tamsulosin for Treatment of Lower Urinary Tract Symptoms in Men: Randomized, Double-Blind, Placebo-Controlled Study
MacDiarmid et al.
Mayo Clin Proc. 2008;83:1002-1010.
ABSTRACT
| FULL TEXT
Update in Geriatric Medicine
Reuben
ANN INTERN MED 2007;147:470-477.
FULL TEXT
Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
Bell and Amarshi
JAMA 2007;297:1192-1192.
FULL TEXT
Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
Chai
JAMA 2007;297:1191-1192.
FULL TEXT
Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
Young and Subramonian
JAMA 2007;297:1192-1193.
FULL TEXT
New Options and Strategies for the Treatment of Urinary Incontinence
Treadway and Canales
Journal of Pharmacy Practice 2007;20:29-48.
ABSTRACT
Possible New Approach to Overactive Bladder in Men
JWatch General 2006;2006:1-1.
FULL TEXT
Improving Men's Health: Evidence and Opportunity.
Fontanarosa and Cole
JAMA 2006;296:2373-2375.
FULL TEXT
|
